



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/554,732	01/05/2007	Christian Hubschwerlen	64391(41925)	9693
21874 7590 09/03/2008 EDWARDS ANGELL PALMER & DODGE LLP P.O. BOX 55874 BOSTON, MA 02205				
EXAMINER ZAREK, PAUL E				
ART UNIT 4161		PAPER NUMBER		
MAIL DATE 09/03/2008		DELIVERY MODE PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/554,732

Applicant(s)

HUBSCHWERLEN ET AL.

Examiner

PAUL ZAREK

Art Unit

4161

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 28-53 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 28-53 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/55/08)
Paper No(s)/Mail Date ____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date ____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____.

DETAILED ACTION

Status of the Claims

1. Claims 1-27 have been canceled by the Applicant. Claim 28-53 were added on 10/28/2005.

Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a piperidine and R3 and R5 are not cyclized.

Group II, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a piperidine and R3 and R5 are cyclized.

Group III, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a piperazine and R3 and R5 are not cyclized.

Group IV, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a piperazine and R3 and R5 are cyclized.

Group V, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a pyrrolidine and R3 and R5 are not cyclized.

Art Unit: 4161

Group VI, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is a pyrrolidine and R3 and R5 are cyclized.

Group VII, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is an azetidine and R3 and R5 are not cyclized.

Group VIII, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is an azetidine and R3 and R5 are cyclized.

Group IX, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is an azepane and R3 and R5 are not cyclized.

Group X, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is an azepane and R3 and R5 are cyclized.

Group XI, claim(s) 28-32 and 34-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is not one of either a piperidine, piperazine, pyrrolidine, azetidine or azepane and R3 and R5 are not cyclized.

Group XII, claim(s) 28-30 and 33-53, drawn to a method of treating a subject suffering or susceptible to anthrax or an infection comprising administering formula I wherein A is not one of either a piperidine, piperazine, pyrrolidine, azetidine or azepane and R3 and R5 are cyclized.

3. The inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Gordeev, et al. (International Application No. WO 02/059116, provided in IDS) teach an embodiment of formula I identical to Example 1 of the instant application (Example 1, pg 24 of the '116 International Application). Gordeev, et al., teach that the compound is an effective treatment for bacterial diseases (abstract). Therefore, the inventions as claimed lack a special technical feature.

Election of Species

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Regardless of the Group elected, a further species election is required:

- the oxazolidinone-quinoline hybrid antibiotic of formula I wherein the identity (where applicable) and location (where applicable) of A, B, D, E, G, K, L, R1, R2, R3, R4, R5, R6, R7, R8, U, V, , X, Y, Z, a, b, c, m, and n are specified.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

5. The claims are deemed to correspond to the species listed above in the following manner:

Groups I, III, V, VII, IX, or XI:	Claims 29-32 and 35-52
Groups II, IV, VI, VIII, or X:	Claims 29-30 and 34-52

The following claim(s) are generic:

regardless of invention elected, Claims 28 and 53 are generic.

6. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Gordeev, et al. (International Application No. WO 02/059116, provided in IDS) teach an embodiment of formula I identical to Example 1 of the instant application (Example 1, pg 24 of the '116 International Application). Gordeev, et al., teach that the compound is an effective treatment for bacterial diseases (abstract). Therefore, the inventions as claimed lack a special technical feature.

7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

8. The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL ZAREK whose telephone number is (571) 270-5754. The examiner can normally be reached on Monday-Thursday, 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, PATRICK NOLAN can be reached on (571) 272-0847. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

PEZ

/Patrick J. Nolan/
Supervisory Patent Examiner, Art Unit 4161